They also offer a GLP-1 only option at $149 per month, which provides compounded semaglutide rather than tirzepatide
Tirzepatide is a dual agonist (GLP-1/GIP), whereas Retatrutide adds a third target??the Glucagon receptor??to further increase energy expenditure
29 A post-hoc analysis of the LEADER trial disclosed that liraglutide reduced both progression of CKD and macroalbuminuria, the latter independent of baseline albuminuria or GFR
Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, et al
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity